Last updated on August 2018

Biomarker for Hunter Disease

Brief description of study

Hunter Syndrome (mucopolysaccharidosis II [MPS II]) is a lysosomal storage disorder caused by reduction or absence of the iduronate-2-sulphatase enzyme has still the problem of the difficulties of a simple and reliable analysis for the primary diagnosis but also for the follow-up of the disease. Especially in the cases of female carriers which have been reported to have some symptoms of MPS II due to skewed X-inactivation makes the diagnosis complex. However, early diagnosis and treatment of disease complications with enzyme replacement therapy can improve quality of life.Therefore the primary aim of our project called "BioHunt" is the development of a new plasma biomarker for the early and sensitive diagnosis of the disease. The secondary aim is the testing for clinical robustness, specificity and long-term stability of the biomarker.Within the scope of the study the investigators would like to collect in the next 12 months from about 80 patient's plasma and in parallel a simple documentation of the clinical data.

Detailed Study Description

Hunter disease (mucopolysaccharidosis type II) is a lysosomal storage disease caused by deficiency of the enzyme iduronate-2-sulphatase. Deficiency of iduronate sulphatase enzyme causes accumulation of the products dermatan sulphate and heparan sulphate in lysosomes leading to cell death. Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. Features of the disease include dwarfism, enlarged liver and spleen, cardiovascular disorders and deafness.

Mutations in the IDS gene located at Xq28 causes loss of the iduronidate sulfatase enzyme. A pseudogene IDS2 also exists 20 kb from the active IDS gene. The pseudogene IDS2 shares homology to exon 2, intron 2, exon 3, intron 3 and intron 7 of the IDS gene.

Mutations that have been reported in the IDS gene in Hunter patients include gene rearrangements caused by recombination with the IDS2 gene (10 per cent patients), deletions of certain exons or the entire IDS gene (10 per cent patients) or small mutations including insertions, deletions and point mutations (80 per cent patients). To detect all possible types of mutations in the IDS gene causing Hunter disease, three procedures are necessary. These include Southern blot to look for gene rearrangements, multiplex dosage analysis to detect large deletions and DHPLC and sequencing to detect small mutations.

An accurate biochemical test is available for the diagnosis of Hunter disease consisting of the analysis of iduronate-2-sulfatase activity in plasma, leucocytes or cultured cells. This test should be considered before molecular analysis is undertaken. Molecular identification of the mutation in individuals with a confirmed diagnosis can be used for carrier testing and prenatal diagnosis in the family. The biochemical test is not reliable for identifying carriers.

Clinical Study Identifier: NCT01330277

Contact Investigators or Research Sites near you

Start Over

Abdelmadjid Benmansour, MD

Pediatric practice
Oran, Algeria
  Connect »

Roberto Giugliani, MD

Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica Recruiting
Porto Alegre, Brazil
  Connect »

Roberto Giugliani, MD

Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
  Connect »

Radka Tincheva, MD

University Pediatric Hospital of Sofia
Sofia, Bulgaria
  Connect »

Arndt Rolfs, MD

University of Rostck, Albrecht-Kossel-Institute for Neuroregeneration
Rostock, Germany
  Connect »

Dimitrios Zafeiriou, MD

Aristotle University of Thessaloniki-Ippokration General Hospital
Thessaloniki, Greece
  Connect »

György Fekete, MD

SOTE Pediatric clinic II, Semmelweis University
Budapest, Hungary
  Connect »

Anil Jalan, MD

NIRMAN, University of Mumbai
Mumbai, India
  Connect »

Yousef Shafeghati, MD

Research center University of Welfare Science, Medical Genetics Department Sarem Women Hospital
Teheran, Iran, Islamic Republic of
  Connect »

Anna Tylki-Szymanska, MD

The Children's Memorial Health Institute, Department of Metabolic Disease
Warsaw, Poland
  Connect »

Adrijan Sarajlija, MD

Mother and Child Health Institute of Serbia- Dr. Vukan Cupic
Novi-Beograd, Serbia
  Connect »